Aura Biosciences closes $69.9M public offering of common stock and warrants

Aura Biosciences, Inc.

Sold 11.7M shares, 3.6M pre-funded warrants, and 3.8M common stock warrants at $4.90 combined price.
Net proceeds of approximately $69.9 million after underwriting discounts and expenses.
Proceeds to advance clinical programs in choroidal melanoma, ocular surface cancers, and bladder cancer.
Cash runway extended into the first half of 2027.
Offering closed on May 16, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.